NCI, NIH Both Win Increases of 15% in 1999 Budget

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 12
Volume 7
Issue 12

BETHESDA, Md-Congress has appropriated the National Cancer Institute $2.93 billion for fiscal year 1999, which began Oct. 1, up from $2.54 billion in fiscal year 1998. The $390 million funding increase represents a raise of 15.35% for NCI.

BETHESDA, Md—Congress has appropriated the National Cancer Institute $2.93 billion for fiscal year 1999, which began Oct. 1, up from $2.54 billion in fiscal year 1998. The $390 million funding increase represents a raise of 15.35% for NCI.

The House and Senate increased the total NIH budget to $15.65 billion, up from $13.62 billion, a hike of $2.03 billion or 14.9%. Congress passed the appropriations several weeks after the new fiscal year began.

The NCI received 19.2% of the total NIH increase in funding. Much of NCI’s additional budget will go to increase both the number and the dollar amounts of extramural research grants and to expand its clinical trials program.

President Clinton proposed increasing NIH funding by 8.7% in his proposed budget. The House then approved a hike of 9.1%, but the final appropriations figure represented a victory for Senator Arlen Specter (R-Pa), who chairs the Senate appropriations subcommittee that oversees NIH’s budget. Senator Specter is a leading advocate of doubling NIH’s budget over the next 5 years and he had argued throughout the year for a 15% increase for the agency.

An advocacy panel, known as the Research Task Force, has recommended quadrupling the government’s spending for cancer research to $10 billion annually over the next 5 years, and had urged a doubling of the current budget.

The 164-member group said that increasing funding to $10 billion, coupled with the implementation of recommendations it has made, would reduce cancer deaths by 25% to 40% over the next 20 years and eventually save “150,000 to 225,000 lives each year in the US.”

The task force was formed as part of The March, the national effort to make cancer the nation’s number one health priority, and co-chaired by Ellen V. Sigal, PhD, who heads Friends of Cancer Research, and Anna D. Barker, PhD, president and CEO of BIO-NOVA, Inc.

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content